SuFu somatic mutations are recognized as novel markers for genomic instability and tumor growth in lung adenocarcinoma
SuFu's rare somatic mutations (~1%) had clinical value and were confirmed as markers of LUAD progression, providing new insights into the pathogenesis of LUAD. Potential therapeutic strategies involving the SuFu-Gli1 axis have also been proposed for precision medicine in the treatment of LUAD.
Authors
- Jian‐Qing He (ORCID: https://orcid.org/0000-0002-0966-1302)
- Mengsi Zhang (ORCID: https://orcid.org/0009-0008-5377-8939)
- Xiangdong Zhou (ORCID: https://orcid.org/0000-0002-4451-5327)
- Yan Wang (ORCID: https://orcid.org/0000-0003-2426-2542)
- Ji‐Hong Liu (ORCID: https://orcid.org/0000-0001-6686-1629)
- Tao Zhang (ORCID: https://orcid.org/0000-0003-2765-2802)
Institutions
- Army Medical University (CN)
- Southwest Hospital (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/tlcr-2025-723
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00